$2.47
8.18% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US28106W1036
Symbol
EDIT

Editas Medicine, Inc. Stock price

$2.47
-1.46 37.15% 1M
+1.14 85.71% 6M
+1.20 94.49% YTD
-0.70 22.08% 1Y
-8.57 77.63% 3Y
-27.94 91.88% 5Y
-15.73 86.43% 10Y
-15.73 86.43% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.22 8.18%
ISIN
US28106W1036
Symbol
EDIT
Industry

Key metrics

Basic
Market capitalization
$241.9m
Enterprise Value
$120.1m
Net debt
positive
Cash
$178.5m
Shares outstanding
87.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.2 | 13.7
EV/Sales
3.1 | 6.8
EV/FCF
negative
P/B
12.6
Financial Health
Equity Ratio
39.3%
Return on Equity
-176.6%
ROCE
-111.2%
ROIC
-
Debt/Equity
3.0
Financials (TTM | estimate)
Revenue
$38.9m | $17.7m
EBITDA
$-154.1m | $-174.3m
EBIT
$-160.8m | $-180.6m
Net Income
$-236.9m | $-183.2m
Free Cash Flow
$-204.9m
Growth (TTM | estimate)
Revenue
-42.0% | -45.3%
EBITDA
25.6% | 25.2%
EBIT
24.5% | 24.4%
Net Income
-22.4% | 22.7%
Free Cash Flow
-19.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-396.1% | -986.5%
EBIT
-413.4%
Net
-608.9% | -1,037.0%
Free Cash Flow
-526.8%
More
EPS
$-2.8
FCF per Share
$-2.3
Short interest
8.5%
Employees
246
Rev per Employee
$130.0k
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Editas Medicine, Inc. forecast:

11x Buy
55%
7x Hold
35%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
55%
Hold
35%
Sell
10%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
39 39
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
9% 9%
156%
- Research and Development Expense 139 139
35% 35%
357%
-154 -154
26% 26%
-396%
- Depreciation and Amortization 6.73 6.73
16% 16%
17%
EBIT (Operating Income) EBIT -161 -161
25% 25%
-413%
Net Profit -237 -237
22% 22%
-609%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana.
Negative
Seeking Alpha
24 days ago
Gene editing seems like a great idea: Instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as Crispr. I previously covered two companies, Crispr Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a Crispr li...
Neutral
GlobeNewsWire
29 days ago
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 246
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today